Treating early-stage TNBC

Rebecca Dent, MD, FRCP, National Cancer Centre Singapore, Singapore, talks on the treatment of triple-negative breast cancer (TNBC) at ESMO Breast 2021. Prof. Dent discusses the advantages of perioperative systemic therapy, including the creation of opportunities for risk-reducing surgeries and restratification in the residual disease setting. Prof. Dent also outlines the ESMO and ASCO guidelines for treatment in the neoadjuvant setting and comments on the optimal systemic therapy, reporting that optimal treatment of lower-risk patients with breast cancer remains to be determined. Finally, Prof. Dent talks on the use of platinum therapy, highlighting data from recent clinical trials, including results from the Phase III BrighTNess trial (NCT02032277) exploring the addition of platinum-based therapy to chemotherapy in patients with early-stage TNBC. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.